KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Liabilities: 2018-2024

Historic Total Liabilities for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $75.4 million.

  • Castle Biosciences' Total Liabilities rose 30.24% to $95.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.7 million, marking a year-over-year increase of 30.24%. This contributed to the annual value of $75.4 million for FY2024, which is 21.47% up from last year.
  • Per Castle Biosciences' latest filing, its Total Liabilities stood at $75.4 million for FY2024, which was up 21.47% from $62.1 million recorded in FY2023.
  • Castle Biosciences' 5-year Total Liabilities high stood at $75.4 million for FY2024, and its period low was $23.6 million during FY2020.
  • In the last 3 years, Castle Biosciences' Total Liabilities had a median value of $62.1 million in 2023 and averaged $61.9 million.
  • As far as peak fluctuations go, Castle Biosciences' Total Liabilities crashed by 31.75% in 2020, and later skyrocketed by 115.05% in 2021.
  • Yearly analysis of 5 years shows Castle Biosciences' Total Liabilities stood at $23.6 million in 2020, then spiked by 115.05% to $50.8 million in 2021, then decreased by 5.22% to $48.2 million in 2022, then climbed by 28.83% to $62.1 million in 2023, then climbed by 21.47% to $75.4 million in 2024.